Research programme: depressive disorders therapeutics - Ache Laboratories

Drug Profile

Research programme: depressive disorders therapeutics - Ache Laboratories

Alternative Names: AZ 02; PDI42

Latest Information Update: 05 Jan 2016

Price : $50

At a glance

  • Originator Ache Laboratories
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Depressive disorders

Most Recent Events

  • 31 Dec 2014 PDI 42 is still in early research for Depressive disorders in Brazil (Ache's annual report,
  • 31 Dec 2013 Early research in Depressive disorders in Brazil (unspecified route) prior to December (Ache's annual report,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top